This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss two trials with a joint IPNA JC session. PREDNOS 2 explores and explodes the steroids use in URTI to prevent relapse practice, while another noninferiority trial reports use of lower dose steroids in managing relapses.
This week, we will discuss the updated 2021 GN guidelines from KDIGO. They have always been the most useful of all GN guidelines. Let’s see what has changed
Steroids are the mainstay of minimal change. Or are they? Lets explore an RCT that bravely challenges the status quo of steroids with tacrolimus monotherapy